Abstract
Background Preclinical, observational, and genetic epidemiological evidence implicate circulating lipids in cancer development. The role of approved and emerging lipid-perturbing medications in cancer risk is unclear.
Patients and methods We employed cis-Mendelian randomization (MR) and colocalisation to evaluate the role of 5 lipid-perturbing drug targets (ANGPTL3, ANGPTL4, APOC3, CETP, PCSK9) in risk of 5 cancers (breast, colorectal, head and neck, ovarian, prostate) in up to 319,661 cases and 348,078 controls. We further triangulated findings using direct measures of pre-diagnostic protein targets in case-cohort analyses in the European Prospective Investigation into cancer and Nutrition (EPIC). To gain mechanistic insight into the role of ANGPTL4 in carcinogenesis, we examined the impact of the ANGPTL4 p.E40K loss-of-function variant on differential gene expression in normal colon tissue in the BarcUVa-Seq project. Finally, we evaluated the association of ANGPTL4 gene expression in colon tumour tissue with all-cause mortality in The Cancer Genome Atlas (TCGA).
Results In analysis of 78,473 cases and 107,143 controls, genetically-proxied circulating ANGPTL4 inhibition was associated with a reduced risk of colorectal cancer (OR per SD decrease: 0.76, 95% CI 0.66-0.89, P = 5.52 x 10-4, colocalisation posterior probability = 0.83). This association was replicated in the EPIC cohort using pre-diagnostic circulating ANGPTL4 concentrations in 977 incident colorectal cancer cases and 4,080 sub-cohort members (HR per log10 decrease: 0.92, 95% CI 0.85-0.99, P = 0.02). In gene set enrichment analysis of differential gene expression in 445 normal colon tissue samples, ANGPTL4 loss-of-function was associated with down-regulation of several biological pathways implicated in cancer (FDR P < 0.05), including those involved in cellular proliferation, epithelial-to-mesenchymal transition, and bile acid metabolism. In analysis of 465 colon cancer patients, lower ANGPTL4 expression in tumour tissue was associated with reduced risk of all-cause mortality (HR per log2 decrease: 0.85, 95% CI 0.73-0.99; P = 0.04). There was little evidence of association of genetically-proxied inhibition of ANGPTL4 or other lipid targets with the other cancer outcomes evaluated.
Conclusion Our integrative proteogenomic and observational analyses suggest a protective role of lower circulating ANGPTL4 concentrations in colorectal cancer risk. These findings support further evaluation of ANGPTL4, an emerging drug target for hypertriglyceridemia, as a potential therapeutic target for colorectal cancer prevention.
Highlights
We used complementary proteogenomic and observational analyses to investigate the effect of lipid-perturbing drug targets on cancer risk
Across all methods there was consistent evidence for a protective role of lower circulating ANGPTL4 concentrations in colorectal cancer risk
Our findings highlight the possibility of repurposing pharmacological ANGPTL4 inhibition as a novel approach for colorectal cancer prevention
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JY and IT are supported by the National Institute for Health and Care Research Imperial Biomedical Research Centre. DW and EL are supported by A*STAR (UIBR), the Academy of Medical Sciences Professorship (APR7_1002) and the Engineering and Physical Sciences Research Council (EP/V029045/1). FMN and VM are supported by the Spanish Association Against Cancer (AECC) Scientific Foundation grant GCTRA18022MORE, the Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), action Genrisk and the Instituto de Salud Carlos III (ISCIII), "Programa FORTALECE del Ministerio de Ciencia e Innovacion", through the project number FORT23/00032.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Access to European Prospective Investigation into Cancer and Nutrition (EPIC) data was granted following submission of a data usage proposal.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online except for case-cohort analyses performed in the European Prospective Investigation into Cancer and Nutrition (EPIC) which required submission of a data usage proposal (epic{at}iarc.who.int).
